Turn Biotechnologies announced today that it created a novel platform for the safe and effective delivery of nucleic acid therapeutics.
Mountain View, California-based Turn said in a news release that the platform represents a “major expansion” of its business.
It designed its eTurna Platform for the next generation of precision medicine. eTurna allows for fine-tuning a variety of cargoes requiring different administration routes targeted to specific tissues nad cells. The company said it will use eTurna to deliver mRNA medicines developed using its epigenetic reprogramming of aging (ERA) platform.
eTurna can also carry other therapeutic cargoes. The company said collaborations to do so would unlock the potential of emerging therapeutics while feeling its expansion.
“Our platform overcomes the ultimate barrier to mRNA medicine by making it possible to deliver therapies precisely to their targets,” said Anja Krammer, Turn Bio CEO. “It is also extremely versatile, capable of encapsulating and stabilizing mRNAs and large cargo to produce formulations that can be developed for a wide array of therapies to transform how we treat disease.”
Turn Bio designed its nanostructure carriers for individual therapies and different routes of administration. It produces unique formulations to precisely steer the right mRNA or cargo to the right organs, tissues and cell types.
Led by Mouhannad Jumaa, Turn Bio’s CMC team developed eTurna. Jumaa serves as EVP of pharmaceutical development/CMC.
“eTurna caps a lifetime of work to develop new ways to deliver therapies more precisely than ever,” said Jumaa. “It overcomes the final obstacles that have prevented transformational therapies from reaching patients. eTurna will help to redefine patient care.”